A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody-Drug Conjugate Exerted Antitumor Activity in a Pancreatic Cancer Xenograft Model
Podocalyxin (PODXL) is a potential diagnostic biomarker and therapeutic target in various tumors. Development of anti-PODXL mAbs has been limited by concerns about potential reactivity with normal tissues. To minimize on-target, off-tumor toxicities and adverse effects, we developed cancer-specific mAbs (CasMabs) against PODXL and demonstrated antitumor efficacy in human tumor xenograft models. In this study, we evaluated humPcMab-60-DXd, an anti-PODXL CasMab conjugated with DXd, a derivative of the topoisomerase I inhibitor exatecan. humPcMab-60-DXd retained cancer-specific reactivity with the pancreatic ductal adenocarcinoma MIA PaCa-2 cell line. Furthermore, humPcMab-60 was internalized into MIA PaCa-2 and inhibited cell proliferation in vitro. In the MIA PaCa-2 xenograft model, humPcMab-60-DXd showed superior antitumor efficacy compared with humPcMab-60. Moreover, humPcMab-60-DXd exhibited dose-dependent antitumor activity without reducing mice body weight. Histological analyses revealed the collapse of the intratumoral structure and a reduction in PODXL expression in the humPcMab-60-DXd-treated xenograft. These results provide the first observation of antitumor efficacy for an anti-PODXL CasMab–drug conjugate, which could facilitate the clinical development of CasMabs for tumor therapy.
Authors
- Takuro Nakamura (ORCID: https://orcid.org/0000-0002-0419-7547)
- Hiroyuki Suzuki (ORCID: https://orcid.org/0000-0003-2646-5132)
- Tomokazu Ohishi (ORCID: https://orcid.org/0000-0002-9039-4474)
- Mika Kato Kaneko (ORCID: https://orcid.org/0000-0002-4158-9208)
- Yukinari Kato (ORCID: https://orcid.org/0000-0001-5385-8201)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3390/ijms272210317
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development